A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?

Clinical Journal of Gastroenterology

Volumn 9, Issue 4, 2016, Pages 252-256

  Hayashi, Kazuhiko ^a   Ishigami, Masatoshi ^a   Ishizu, Yoji ^a   Kuzuya, Teiji ^a   Honda, Takashi ^a   Nishimura, Daisaku ^b   Goto, Hidemi ^a   Hirooka, Yoshiki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Clinical Laboratory   (Japan)

Author keywords

Direct acting antivirals; Hepatitis B virus reactivation; Hepatitis C virus

Indexed keywords

ASUNAPREVIR; DACLATASVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ACUTE HEPATITIS B; AGED; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CHRONIC HEPATITIS C; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); LIVER FUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; ACUTE DISEASE; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; MIXED INFECTION; PHYSIOLOGY; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

ACUTE DISEASE; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; SULFONAMIDES; VIRUS ACTIVATION;

EID: 84975229588     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-016-0657-4     Document Type: Article

References (27)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395–403.
2. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.
3. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–11129.
4. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68–9.
5. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.
6. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975;2:528–30.
7. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304–6.
8. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;46:489–91.
9. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742–8.
10. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–23.
11. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.
12. Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52–6.
13. Liu CJ, Chen PJ, Chen DS, et al. Hepatitis B virus reactivation post-cancer chemotherapy: pathogenesis and management. Hepatol Int. 2013;7:316–26.
14. Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719–29.
15. Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9(11):e112647.
16. Tamada Y, Yatsuhashi H, Masaki N, et al. Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut. 2012;61:765–73.
17. Yotsuyanagi H, Okuse C, Yasuda K, et al. Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol. 2005;77:39–46.
18. Hayashi K, Katano Y, Takeda Y, et al. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J Med Virol. 2007;79:366–73.
19. Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2015;61:823–33.
20. Colson P, Borentain P, Coso D, et al. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology. 2015;484:354–63.
21. Hayashi K, Ishigami M, Ishizu Y, et al. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. J Gastroenterol. 2016 [Epub ahead of print].
22. Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57:141–50.
23. Kamitsukasa H, Iri M, Tanaka A, et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol. 2015;87:589–600.
24. Mochida S, Nakao M, Nakayama N, et al. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol. 2016 [Epub ahead of print].
25. Sagnelli E, Coppola N, Marrocco C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: areciprocal viral interaction. J Clin Virol. 2006;35:317–20.
26. De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27–30.
27. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715–25.